Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...
Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of ...
Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...